**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 20752**

**Manuscript Type:** **ORIGINAL ARTICLE**

***Basic Study***

**Interleukin-22 contributes to liver regeneration in concanavalin A-mediated murine hepatitis model after hepatectomy**

Zhang YM *et al*. IL-22 promote liver regeneration of CP

Ya-Min Zhang, Zi-Rong Liu, Zi-Lin Cui, Chao Yang, Long Yang, Yang Li, Zhong-Yang Shen

**Yan-Min Zhang, Zi-Lin Cui, Long Yang, Yang Li, Zhong-Yang Shen,** Department of Hepatobiliary Surgery, First Central Hospital, Tianjin 300192, China

**Zi-Rong Liu, Chao Yang,** First Central Clinic of Tianjin Medical University, Tianjin 300192, China

**Author contributions:** Zhang YM and Liu ZR contributed equally to this work; Zhang YM, Liu ZR and Cui ZL designed the research; Zhang YM, Liu ZR, Yang C, Yang L and Li Y performed the research; Zhang YM, Liu ZR, Yang L and Shen ZY contributed new reagents and analytic tools; Zhang YM, Liu ZR, Yang C, Cui ZL and Li Y analyzed the data; Zhang YM and Liu ZR wrote the paper.

**Supported by** National Natural Science Foundation of China, No. 81370576; and Application foundation and advanced technology research plan of Tian jin, China, No.14JCYBJC24800.

**Institutional review board statement:** This work has been approved by the Ethics Committee of Tianjin First Central Hospital.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Institute of laboratory animal sciences, CAMS and PUMC (IACUC protocol number: SCXK[Jing]2014-0004).

**Conflict-of-interest statement:** The authors declare no conflcts of interest.

**Data sharing statement:** No additional unpublished data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Zi-Rong Liu, Postgraduate,** First Central Clinic of Tianjin Medical University, No. 24 Fukang road, Nankai district, Tianjin 300192, China. [liuzirong0730@163.com](mailto:liuzirong0730@163.com)

**Telephone:** + 86-13132206635

**Received:** Juen 20, 2015

**Peer-review started:** June 21, 2015

**First decision:** July 10, 2015

**Revised:** July 21, 2015

**Accepted:** October 23, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM**: To investigate the therapeutic effects and mechanisms of interleukin (IL)-22 in liver regeneration with mice with concanavalin A (ConA)-mediated liver injury following 70% hepatectomy.

**METHODS**: Mice were injected intravenously with ConA at 10 μg/g body weight 4 days before 70% hepatectomy to create the hepatitis model, and recombinant IL-22 was injected at 0.125 μg/g body weight 30 min prior to 70% hepatectomy to create the therapy model. The control animals received an intravenous injection of an identical volume of saline.

**RESULTS**: In the mice, the IL-22 treatment prior to the 70% hepatectomy performed under general anesthesia resulted in reductions in the biochemical and histological evidence of liver injury, the earlier proliferation of chain nuclear antigen expression and accelerated recovery of liver mass. IL-22 pretreatment also significantly induced signal transducer and activator of transcription factor 3 (STAT3) activation and increased the expressions of a variety of mitogenic proteins, such as cyclin D1. Furthermore, *AFP* mRNA expression was significantly elevated after IL-22 treatment.

**CONCLUSION**: In this study, we demonstrated that IL-22 is a survival factor for hepatocytes and also prevents and repairs liver injury by enhancing pro-growth pathways *via* STAT3 activation. Treatment with IL-22 protein may represent a novel therapeutic strategy for preventing liver injury patients with liver disease who have undergone hepatectomy.

**Key words:** Interleukin-22; Concanavalin A; Partial hepatectomy; Liver regeneration

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Interleukin (IL)-22 appears to play a protective role in inflammation and has also been demonstrated to have proliferative effects in a hepatocyte cell line, however, it has rarely been reported that the protective and proliferative effects exist simultaneously. In this article, we investigated the therapeutic effects and mechanisms of IL-22 in liver regeneration with mice with concanavalin A-mediated liver injury following 70% hepatectomy. IL-22 played protective and survival roles against liver injury in this model.

Zhang YM, Liu ZR, Cui ZL, Yang C, Yang L, Li Y, Shen ZY. Interleukin-22 contributes to liver regeneration in concanavalin A-mediated murine hepatitis model after hepatectomy. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Interleukin-22 (IL-22) is an inducible cytokine of the IL-10 superfamily that was identified by the Belgian Renauld team as early as 2000 and was previously known as the IL-10-related factor from T cells[1]. IL-22 is produced by activated T cells and natural killer (NK) cells and acts *via* a heterodimeric receptor complex consisting of IL-22 receptor-α (IL-22Rα) and IL-10 receptor-β (IL-10Rβ).

IL-22 has been demonstrated to exhibit a variety of effects. IL-22 appears to play an important role in inflammation and has also been noted to exert proliferative effects in a hepatocyte cell line *in vitro*[2-5]. In 2004, the Bin Gao team demonstrated that IL-22 expression is significantly induced in T cell-mediated hepatitis and that IL-22 blockade markedly enhances liver injury in this model, while the administration of recombinant IL-22 prevents concanavalin A (ConA)-induced liver injury[5]. These findings suggest that IL-22 acts as a protective cytokine that attenuates liver injury in T cell-mediated hepatitis. Furthermore, *in vitro* study has also revealed that IL-22 has no obvious toxicity on liver cell lines or primary liver cells and has proliferative and survival effects on these cells. Additionally, a recent study supported a potential therapeutic role for IL-22 as a protective factor in hepatic resection. The authors of this study observed significant increases in hepatic IL-22 receptor expression and serum IL-22 levels after 70% hepatectomy and a significant decrease in liver regeneration after IL-22 blockade[6]. However, the precise mechanism of IL – 22-mediated liver protection remains unclear.

Currently, all of the evidence supporting the role of IL-22 in liver protection is from liver injury models, and the evidence for the liver proliferative effects is almost entirely from the simple 2/3 liver resection model without other injury. However, clinical patients with hepatectomy nearly always have liver disease and thus significantly decreased liver regeneration abilities. In this article, we sought to investigate the therapeutic effects and mechanisms of IL-22-mediated liver regeneration in mice with ConA-mediated liver injury following 70% hepatectomy.

**MATERIALS AND METHODS**

***Materials***

Recombinant IL-22 protein was purchased from Pepro Tech Inc (State of New Jersey, USA). Anti-STAT3, Cyclin D1 and proliferating cell nuclear antigen (PCNA) antibodies were obtained from Cell Signaling Technology Inc (CST, USA). Female C57/BL6 mice were purchased from HFK Bioscience Co. Ltd. (Beijing, China).

***Seventy percent hepatectomy model***

Female C57/BL6 mice (6–8 wk of age, 20-25 g) were maintained under specific pathogen-free conditions with free access to water and food before each experiment. The animals were anesthetized with [chloral](javascript:void(0);) [hydrate](javascript:void(0);) injections. After a midline incision was created under microscopic guidance, and the middle and left hepatic lobe of the liver were fully freed, 7-0 vascular sutures were used to ligate the branches of hepatic artery and portal vein of the median and left lateral lobes of the liver. Next, the bile duct was ligated with 7-0 vascular sutures, and the gall bladder was removed. Finally, the median and left lateral lobes of the liver were resected after a 4-0 silk suture ligation was secured around the base of each lobe.

***ConA-mediated liver injury model***

ConA was injected intravenously at 10 μg/g body wt 4 d before the operation, and the 70% hepatectomy model animals received intravenous injections of identical volumes of saline.

*ConA-mediated liver injury and 70% hepatectomy model*

ConA was injected intravenously at 10 μg/g body wt, and the 70% hepatectomies were performed 4 d later.

*IL-22 treatment model*

Four days after the intravenous injections of 10 μg/g body wt ConA, recombinant murine IL-22 was injected intravenously at 0.125 μg/g body wt 30 min prior to 70% hepatectomy. The control animals received intravenous injections of identical volumes of saline.

***Liver weight/body weight ratio***

At 32 h, 40 h, 48 h, 1 wk, and 2 wk, the mice were humanely killed under general anesthesia once moribund. The liver and body weights of all mice in each group were measured, and the liver weight/body weight was then calculated to observe the liver regeneration conditions.

***Examination of liver injury***

To assess the damage to the hepatic parenchyma, the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using a serum analyzer (Cobas-Mira Plus, Roche, Manheim, Germany). The liver specimens were fixed in 10% buffered formalin and embedded in paraffin, and the paraffin embedded liver tissue sections were then stained with hematoxylin and eosin for histological examinations.

***Immunohistochemistry***

The tissue specimens were fixed in neutral buffered formalin and then embedded in paraffin. The 4-µm paraffin sections were deparaffinized in xylene and rehydrated in a graded series of alcohol. Endogenous peroxidase was inhibited with 0.3% H2O2 in methanol. The sections were heated in a microwave oven (in 10 mM citrate buffer, pH 6.0) for 20 min for epitope retrieval. The primary antibodies were against PCNA (1:4000; Abcam). The slides were incubated with anti-mouse/rabbit biotinylated bridging antibodies (dilution: 1/200, DAKO) for 60 min. The sections were counterstained with Mayer’s hematoxylin. PCNA antigen expression levels were evaluated by counting the positively stained staining cells (H&E) in the portal triads of five high-power fields (HPFs) per slide, and the results are expressed as the average number of positive cells/HPF.

***Quantitative real-time PCR analysis***

RNA was extracted from snap-frozen liver tissue samples using the TRIzol technique. Five micrograms of RNA were reverse-transcribed into cDNA using oligo-dT primers with a Superscript III First-Strand Synthesis System (Invitrogen). Quantitative real-time PCR was performed with iCycler IQ system (Bio-Rad, Hercules, CA). The primers sequence for AFP were 5’- CAA AGC ATT GCA CGA AAA TGA G-3’ (forward) and 5’-AAC AAA CTG GGT AAA GGT GAT GGT-3’ (reverse). β-actin was measured as a housekeeping gene. The cycling conditions comprised a 5 min polymerase activation at 95°C, 40 cycles of 95 °C for 5 s and 60°C for 30 s and a single fluorescence measurement. Melting curve analysis based on increasing the temperature from 60 to 95 °C at a rate of 0.5 °C/s with continuous fluorescence measurement revealed a single, narrow peak for the suspected fusion temperature.

*Western blot*

The mice were euthanized at baseline and at 32 h, 40 h, 48 h, 1 wk and 2 wk after hepatectomy, and liver samples were obtained for Western blot analyses. The proteins were extracted from the liver tissues and quantified using a protein assay (Bio-Rad Laboratories, CA). The protein samples (30 μg) were fractionated by SDS-PAGE and transferred to a nitrocellulose membrane. Immunoblotting was conducted using antibodies against STAT3 and CyclinD1 (all purchased from Cell Signaling Technology, Inc. USA). The results were visualized *via* an enhanced chemiluminescent detection system (Pierce ECL Substrate Western blot detection system, Thermo Scientific, IL) and exposure to autoradiography film (Kodak XAR film).

***Statistical analysis***

All parametric data are presented as the mean ± the standard deviation. The data were analyzed for significance using Student’s t tests. One-way analyses of variance with Fisher’s protected least significant difference (PLSD) tests were used to compare the means. The log-rank test was applied to the compare survival curves. Differences were considered statistically significant when *P* < 0.05.

**RESULTS**

***Effects of IL-22 on*** ***the liver weight/body weight ratio after partial hepatectomy***

At 32 h, 40 h, 48 h, 1 wk, or 2 wk, the mice were humanely killed humanely under general anesthesia once moribund. The liver and body weights were measured, and the liver weight/body weight ratios were then calculated. As illustrated in Figure 1, increases in the liver weight/body weight ratios were observed in the PHX, ConA + PHX and ConA + PHX + IL-22 groups, all groups returned to normal liver weights by 2 w. Compared with the ConA + PHX group, the ratio of the ConA + PHX + IL-22 group increased more rapidly, and significant differences between these two groups were observed at 40 h, 48 h, 1 wk and 2 wk. Similarly, compared to the ConA + PHX group, the ratios of the PHX group increased more rapidly, and the differences reached significance at 48 h or 1 wk. However, the increase in the PHX group was less than that in the ConA + PHX group at 32 h. These data correlated with the cellular swelling in the liver at 32 h in the ConA + PHX group.

***Effects of IL-22 on liver damage following partial hepatectomy***

At 32 h, 40 h, 48 h, 1 wk and 2 wk after 70% hepatectomy, serum was collected, and the ALT and AST levels were measured *via* biochemical analyses. As illustrated in Figure 2, compared with the ConA + PHX group, the ALT and AST serum levels in the ConA + PHX + IL-22 group were reduced, and these differences were significant at all of the time points. Furthermore, with the recombinant IL-22 pretreatment, the decreases in the ALT and AST levels of the ConA + PHX + IL-22 group were significantly greater than those of the ConA and PHX groups at 40 h, 48 h and 1wk.

We also the histologic features of the liver with hematoxylin-eosin (HE) staining. As illustrated in Figure 3, the HE staining of the ConA + PHX group demonstrated severe sinusoidal narrowing that was noted as early as 32 h after hepatectomy. By 48 h, swelling, nuclear condensation and laminar necrosis of the hepatocytes were observed in addition to the near-total loss of the hepatic sinusoids. By 2 w, the hepatic sinusoids and the complete structure of the hepatic lobule were not observed in the hepatocytes. In contrast, the HE staining of the ConA + PHX + IL-22 group revealed much less evidence of injury at 48 h; the cytoplasm was preserved, and some less severe swelling was present. At 2 wk, normal nuclear morphologies, hepatic sinusoids, complete structures of the hepatic lobules and significant regeneration in the hepatocytes were observed.

***Effects of IL-22 on hepatocyte proliferation after partial hepatectomy***

Hepatocyte proliferation was determined by the expression of PCNA, which is a nuclear antigen that is associated with hepatocyte proliferation. As illustrated in Figure 4, the PCNA labeling indices in the four groups began to increase postoperatively and peaked at 48 h. Compared with the ConA + PHX group, the PCNA labeling indices were significantly increased in the ConA, PHX and ConA + PHX + IL-22 groups at all of the time points, particularly at 32, 40, and 48 h. Furthermore, the PCNA levels in the ConA + PHX + IL-22 group increased to greater extents than those of the ConA and PHX groups at 32 h, 40 h and 48 h.

***Effects of IL-22 on AFP mRNA expression after partial hepatectomy***

The mice underwent 70% hepatectomy or sham laparotomy, and quantitative analysis of the liver AFP mRNA expression was performed with real-time RT-PCR. At 32 h, 40 h, 48 h, 1 wk, and 2 wk, the hepatic AFP mRNA expressions in the ConA + PHX group were 0.55 ± 0.06, 0.93 ± 0.08, 1.72 ± 0.11, 0.66 ± 0.05 and 0.43 ± 0.04, respectively. In the IL-22 pretreatment group, the corresponding values were 0.74 ± 0.08, 1.81 ± 0.14, 2.80 ± 0.26, 0.86 ± 0.05 and 0.51 ± 0.03. Figure 5 illustrates that the AFP mRNA expression began at 32 h and had significantly increased by 48 h after hepatectomy in all four groups. Additionally, the AFP mRNA levels in the ConA + PHX + IL-22 group were significantly increased at 32 h, 40 h, 48 h and 1 wk after partial hepatectomy compared with the ConA + PHX group.

***Effects of IL-22 on STAT3 and CyclinD1 activations after partial hepatectomy***

The activations of the STAT3 and CyclinD1 were measured using Western Blot analysis to assess the effects of IL-22 after partial hepatectomy. As illustrated in Figure 6, no significant activations of STAT3 and CyclinD1 were observed at 32 h after partial hepatectomy in the ConA + PHX group, and these activations increased gradually at 48 h and 2 wk. Although STAT3 and CyclinD1 activations were apparent in the remnant livers of the other three groups, STAT3 and CyclinD1 were activated much earlier in the ConA + PHX + IL-22 group than the PHX and ConA groups. Furthermore, among the four groups, the STAT3 and CyclinD1 levels exhibited the greatest increases in the ConA + PHX + IL-22 group and the smallest increases in the ConA + PHX group across all of the time points.

**DISCUSSION**

IL-22 has previously been shown to have a variety of effects. IL-22 appears to play a protective role in inflammation[7-10] and has also been demonstrated to have proliferative effects in a hepatocyte cell line[11]. Hepatectomy in T cell-mediated hepatitis induced by concanavalin A models clinical hepatectomy with liver disease well. We demonstrated that IL-22 acts as a protective cytokine that attenuates liver injury in this model. The present study revealed that pre-treatment with IL-22 prior to hepatectomy significantly decreases the serum ALT and AST levels and increases the serum ALB level following 70% hepatectomy. Our findings suggest that IL-22 plays a protective role against liver injury in ConA-induced T cell hepatitis following 70% hepatectomy and that IL-22 is a survival factor for hepatocytes. With the administration of exogenous IL-22, the liver weight/body ratio increased significantly and returned to the normal level by 2 wk. Additionally, the nuclear morphologies, hepatic sinusoids, complete structures of the hepatic lobules returned to normal, and significant regeneration was observed in the hepatocytes. In contrast, the ConA + PHX group that was not administered exogenous IL-22 exhibited swelling, nuclear condensation and laminar necrosis of the hepatocytes and a near-total loss of the hepatic sinusoids.

In the liver, IL-22 plays an important role in the acute-phase response and possibly also plays a role in the promotion of liver regeneration[2,6,12,13]. IL\_22 acts *via* a heterodimeric receptor complex that consists of IL-22 receptor-α (IL-22Rα) and IL-10 receptor-β (IL-10Rβ)[2,5,14,15]. Examinations of the downstream signaling events following IL-22 administration in the context of partial hepatectomy demonstrated an increase in stat-3 activation. A substantial volume of published evidence supports the notion of STAT3-mediated cell survival and proliferation[16-21]. Our present investigation revealed that the injection of IL-22 rapidly induced STAT3 activation in the liver and that STAT3 induced the expression of genes that are important for cell cycle progression (*e.g*., cyclinD1) and concurrently significantly increased PCNA staining to eventually promote cell survival and proliferation. These findings suggest that IL-22 was also partially responsible for hepatic STAT3 activation in this model. Thus, the activation of STAT3 by IL-22 was likely responsible for the protective role of IL-22 in the hepatocytes.

Alpha fetal protein (AFP) is a specific marker of liver cancer tumors and is closely related to individual development, tissue regeneration, apoptosis and tumorigenesis[22-25]. The main role of AFP in liver regeneration is the regulation hepatocyte growth. It has also been demonstrated that in the context of the synergy of various growth factors, AFP mediates cell growth regulation *via* an interaction with a special cell membrane receptor that results in the uptake of arachidonic acid and AFP into the cell. The process provides the necessary substrate and signal transduction for the M phase of mitosis[26,27]. Our present study found that following pretreatment with recombinant IL-22, AFP mRNA begin to be expressed from 32 h, and this expression increased significantly by 48 h after hepatectomy. This increase in expression was probably due to the loss of the negative regulation of the transcription inhibitory factor. This expression trend reflects the promotion of cell proliferation in the liver by AFP mRNA. These findings suggest that IL-22 can decrease the expression of the transcription inhibitory factor to induce the expression of AFP mRNA and provide the necessary material basis for mitosis and thus eventually promote cell survival and proliferation.

In summary, the model of hepatectomy in T cell-mediated hepatitis induced by concanavalin A simulates clinical hepatectomy with liver disease accurately, and our findings suggest that IL-22 played protective and survival roles against liver injury in this model. Thus, IL-22 treatment should be considered to be a novel therapeutic option for liver injury and regeneration.

**COMMENTS**

***Background***

Interleukin (IL)-22 appears to play a protective role in inflammation and has also been demonstrated to exert proliferative effects in a hepatocyte cell line; however, it has rarely been reported that the protective and proliferative effects exist simultaneously. In this article, the authors sought to investigate the therapeutic effects and mechanisms of IL-22 in liver regeneration with mice with concanavalin A (ConA)-mediated liver injury following 70% hepatectomy.

***Research frontiers***

IL-22 has also been demonstrated to play a protective role in inflammation and proliferative effects in a hepatocyte cell line, however, it has rarely been reported that the protective and proliferative effects exist simultaneously.

***Innovations and breakthroughs***

In this article, the authors investigated the therapeutic effects and mechanisms of IL-22 in liver regeneration with mice with ConA-mediated liver injury following 70% hepatectomy. IL-22 was demonstrated to play protective role and proliferative effects together.

***Applications***

IL-22 treatment should be considered to be a novel therapeutic option for liver injury and regeneration on clinic.

***Peer-review***

In this study, the authors demonstrated that IL-22 is a valuable factor for hepatocyte proliferation and can protect liver from injury induced by ConA. The work is well-done and provides the interesting results.

**REFERENCES**

1 **Dumoutier L**, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. *J Immunol* 2000; **164**: 1814-1819 [PMID: 10657629 DOI: 10.4049/jimmunol.164.4.1814]

2 **Ki SH**, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, Gao B. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. *Hepatology* 2010; **52**: 1291-1300 [PMID: 20842630 DOI: 10.1002/hep.23837]

3 **Yang L**, Zhang Y, Wang L, Fan F, Zhu L, Li Z, Ruan X, Huang H, Wang Z, Huang Z, Huang Y, Yan X, Chen Y. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. *J Hepatol* 2010; **53**: 339-347 [PMID: 20452699 DOI: 10.1016/j.jhep.2010.03.004]

4 **Zenewicz LA**, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. *Immunity* 2007; **27**: 647-659 [PMID: 17919941 DOI: 10.1016/j.immuni.2007.07.023]

5 **Radaeva S**, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. *Hepatology* 2004; **39**: 1332-1342 [PMID: 15122762 DOI: 10.1002/hep.20184]

6 **Ren X**, Hu B, Colletti LM. IL-22 is involved in liver regeneration after hepatectomy. *Am J Physiol Gastrointest Liver Physiol* 2010; **298**: G74-G80 [PMID: 19875704 DOI: 10.1152/ajpgi.00075.2009]

7 **Boniface K**, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. *J Immunol* 2005; **174**: 3695-3702 [PMID: 15749908 DOI: 10.4049/jimmuol.174.6.3695]

8 **Brand S**, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S, Herrmann K, Seiderer J, Ochsenkühn T, Göke B, Auernhammer CJ, Dambacher J. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. *Am J Physiol Gastrointest Liver Physiol* 2006; **290**: G827-G838 [PMID: 16537974 DOI: 10.1152/ajpgi.00513.2005]

9 **Chung Y**, Yang X, Chang SH, Ma L, Tian Q, Dong C. Expression and regulation of IL-22 in the IL-17-producing CD4 + T lymphocytes. *Cell Res* 2006; **16**: 902-907 [PMID: 17088898 DOI: 10.1038/sj.cr.7310106]

10 **Liao SC**, Cheng YC, Wang YC, Wang CW, Yang SM, Yu CK, Shieh CC, Cheng KC, Lee MF, Chiang SR, Shieh JM, Chang MS. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. *J Immunol* 2004; **173**: 6712-6718 [PMID: 15557163 DOI: 10.4049/jimmunol.173.11.6712]

11 **Brand S**, Dambacher J, Beigel F, Zitzmann K, Heeg MH, Weiss TS, Prüfer T, Olszak T, Steib CJ, Storr M, Göke B, Diepolder H, Bilzer M, Thasler WE, Auernhammer CJ. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. *Am J Physiol Gastrointest Liver Physiol* 2007; **292**: G1019-G1028 [PMID: 17204547 DOI: 10.1152/ajpgi.00239.2006]

12 **Moh A**, Iwamoto Y, Chai GX, Zhang SS, Kano A, Yang DD, Zhang W, Wang J, Jacoby JJ, Gao B, Flavell RA, Fu XY. Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery. *Lab Invest* 2007; **87**: 1018-1028 [PMID: 17660847 DOI: 10.1038/labinvest.3700630]

13 **Zimmers TA**, McKillop IH, Pierce RH, Yoo JY, Koniaris LG. Massive liver growth in mice induced by systemic interleukin 6 administration. *Hepatology* 2003; **38**: 326-334 [PMID: 12883476 DOI: 10.1053/jhep.2003.50318]

14 **Wolk K**, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. *Immunity* 2004; **21**: 241-254 [PMID: 15308104 DOI: 10.1016/j.immuni.2004.07.007]

15 **Wolk K**, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. *Semin Immunopathol* 2010; **32**: 17-31 [PMID: 20127093 DOI: 10.1007/s00281-009-0188-x]

16 **Ransohoff DF**. Colon cancer in ulcerative colitis. *Gastroenterology* 1988; **94**: 1089-1091 [PMID: 3345879]

17 **Grivennikov S**, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer Cell* 2009; **15**: 103-113 [PMID: 19185845 DOI: 10.1016/j.ccr.2009.01.001]

18 **Abraham C**, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. *Gastroenterology* 2011; **140**: 1729-1737 [PMID: 21530739 DOI: 10.1053/j.gastro.2011.02.012]

19 **Morrison PJ**, Ballantyne SJ, Kullberg MC. Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. *Immunology* 2011; **133**: 397-408 [PMID: 21631495 DOI: 10.1111/j.1365-2567.2011.03454.x]

20 **Acosta-Rodriguez EV**, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. *Nat Immunol* 2007; **8**: 942-949 [PMID: 17676045 DOI: 10.1038/ni1496]

21 **Das J**, Ren G, Zhang L, Roberts AI, Zhao X, Bothwell AL, Van Kaer L, Shi Y, Das G. Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. *J Exp Med* 2009; **206**: 2407-2416 [PMID: 19808254 DOI: 10.1084/jem.20082286]

22 **Liu L**, Zhang CZ, Cai M, Fu J, Chen GG, Yun J. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. *PLoS One* 2012; **7**: e41293 [PMID: 22829937 DOI: 10.1371/journal.pone.0041293]

23 **Spear BT**. Alpha-fetoprotein gene regulation: lessons from transgenic mice. *Semin Cancer Biol* 1999; **9**: 109-116 [PMID: 10202132 DOI: 10.1006/scbi.1998.0087]

24 **Boss JH**, Rosenmann E, Zajicek G. Alpha-fetoprotein and liver cell proliferation in rats fed choline-deficient diet. *Z Ernahrungswiss* 1976; **15**: 211-216 [PMID: 61657]

25 **Yuan Q**, Loya K, Rani B, Möbus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, Cantz T, Sharma AD. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. *Hepatology* 2013; **57**: 299-310 [PMID: 22821679 DOI: 10.1002/hep.25984]

26 **Karvountzis GG**, Redeker AG. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis. *Ann Intern Med* 1974; **80**: 156-160 [PMID: 4811790 DOI: 10.7326/0003-4819-80-2-156]

27 **Shen H**, Luan F, Liu H, Gao L, Liang X, Zhang L, Sun W, Ma C. ZHX2 is a repressor of alpha-fetoprotein expression in human hepatoma cell lines. *J Cell Mol Med* 2008; **12**: 2772-2780 [PMID: 18194454 DOI: 10.1111/j.1582-4934.2008.00233.x]

**P-Reviewer:** Mensah-Brown EPK, Wang GY **S-Editor:** Yu J

**L-Editor:** **E-Editor:**

**A**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **PO** | **PHX** | **ConA** | **ConA + PHX** | **ConA + PHX + IL-22** |
| 32 h | 2.50 ± 0.20c | 5.10 ± 0.08 | 2.78 ± 0.10 | 2.68 ± 0.12 |
| 40 h | 3.03 ± 0.15 | 5.08 ± 0.10 | 2.95 ± 0.14 | 3.16 ± 0.17a |
| 48 h | 3.26 ± 0.13a | 5.05 ± 0.08 | 3.09 ± 0.14 | 3.34 ± 0.13c |
| 1 wk | 4.01 ± 0.15a | 4.84 ± 0.16 | 3.78 ± 0.10 | 4.19 ± 0.14c |
| 2 wk | 5.05 ± 0.17 | 4.97 ± 0.14 | 4.89 ± 0.12 | 5.14 ± 0.16a |

B

C:\Users\lzr\Desktop\1.tif

**Figure 1 Liver weight/body weight ratios following partial hepatectomy.** A and B: Increases in the liver weight/body weight ratio were observed in the PHX, concanavalin A (ConA) + PHX and ConA + PHX + interleukin (IL)-22 groups, and all groups returned to normal liver weights by 2 wk. Compared with the ConA + PHX group, the ConA + PHX + IL-22 group exhibited greater increases that reached significance at 40 h, 48 h, 1 wk and 2 wk (a*P <* 0.05); these differences were particularly notable at 48 h and 1 wk (c*P <* 0.01). The increases in the PHX group were significantly different from those in the ConA + PHX group at 48 h and 1 wk (a*P <* 0.05); however, the increase in the PHX group at 32 h was less than that in the ConA + PHX group (c*P <* 0.01). These data were correlated with the cellular swelling in the liver at 32 h in the ConA + PHX group.


A B

C:\Users\baishideng-2014\Desktop\2a.tif **C:\Users\lzr\Desktop\ALT22.tif**

C D

C:\Users\baishideng-2014\Desktop\2c.tifC:\Users\lzr\Desktop\AST线性2d.tif

**Figure 2 Serum alanine aminotransferase and aspartate aminotransferase levels after partial hepatectomy.** A-D: Decreases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were observed after 32 h, particularly from 40 h to 1 wk. Compared to the concanavalin A (ConA) + PHX group, the serum ALT and AST levels of the ConA + PHX + interleukin (IL)-22 group decreased, and the difference were significant at all time points (c*P <* 0.01). Furthermore, with the recombinant IL-22 pretreatment, the ALT and AST levels in the ConA + PHX + IL-22 group decreased to significantly greater extents than the levels in the ConA and PHX groups at 40 h, 48 h and 1 wk (a*P <* 0.05).




**Figure 3 Representative hematoxylin and eosin staining of the remnant livers after partial hepatectomy.** The PHX, concanavalin A (ConA), ConA + PHX and ConA + PHX + interleukin (IL)-22 groups, respectively, at 48 h after partial hepatectomy (a-d); The PHX, ConA, ConA + PHX and ConA + PHX + IL-22 groups, respectively, at 2 wk after partial hepatectomy (e-h).

**A**

a b

**C:\Users\baishideng-2014\Desktop\4.tifC:\Users\lzr\Desktop\柱4a.tifC:\Users\lzr\Desktop\线4b.tif**

**B**


****

**Figure 4 Proliferating cell nuclear antigen labeling indices in the remnant livers after partial hepatectomy.** A: Compared with the concanavalin A (ConA) + PHX group, the proliferating cell nuclear antigen (PCNA) labeling indices were significantly increased in the ConA, PHX and ConA + PHX + interleukin (IL)-22 groups at all of the time points (a*P <* 0.05), particularly at 32, 40, and 48 h (c*P <* 0.01). Furthermore, the increases in the PCNA levels in the ConA + PHX + IL-22 group were significantly greater than those in the ConA and PHX groups at 32 h, 40 h and 48 h (a*P <* 0.05); B: PCNA labeling of the cells at 32 h after hepatectomy in the PHX, ConA, ConA + PHX and ConA + PHX + IL-22 groups, respectively (a-d); PCNA labeling of the cells at 48 h after hepatectomy in the PHX, ConA, ConA + PHX and ConA + PHX + IL-22 groups, respectively (e-h).

a b

C:\Users\baishideng-2014\Desktop\5.tifC:\Users\lzr\Desktop\线性英5b.tif

**Figure 5 Hepatic *AFP* mRNA expression in the remnant liver after partial hepatectomy.** A, B: *AFP* mRNA expression began at 32 h and significantly increased to peak at 48 h after hepatectomy. With the interleukin (IL)-22 pretreatment, the AFP mRNA levels significantly increased at 32 h after partial hepatectomy compared with the concanavalin A (ConA) + PHX group (a*P <* 0.05), and marked increases were observed at 40 h, 48 h and 1 wk (c*P <* 0.01). However, the difference was not significant at 2 wk (*P* > 0.05).



**Figure 6 Western blot detection of the activations of STAT3 and CyclinD1 in the remnant livers after partial hepatectomy.** With the administration of interleukin (IL)-22, STAT3 and CyclinD1 were activated much earlier, and the most significant increases in the four groups were observed at 32 h, 48 h, and 2 wk; whereas the least significant increases were observed in the concanavalin A (ConA) + PHX group at all of the time points.